diphtheria and tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine (Kinrix, Quadracel, DTaP/ IPV)
Classes: Vaccines, Combos
- Dosing and uses of Kinrix, Quadracel (diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine)
- Kinrix, Quadracel (diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine) adverse (side) effects
- Warnings
- Pregnancy
- Pharmacology of Kinrix, Quadracel (diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine)
Dosing and uses of Kinrix, Quadracel (diphtheria and tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine)
Adult dosage forms and strengths
Not indicated for adults
Pediatric dosage forms and strengths
diphtheria toxoid/tetanus toxoid/inactivated pertussis toxin (PT)/filamentous hemagglutinin (FHA)/pertactin, type 1 poliovirus (Mahoney)/type 2 poliovirus (MEF-1)/type 3 poliovirus (Saukett)
suspension for IM injection
- Kinrix: (25 Lf/10 Lf/25 mcg/25 mcg/8 mcg/40 D-antigen units/8 D-antigen units/32 D-antigen units)/0.5mL
- Quadracel: (15 Lf/5 Lf/20 mcg/25 mcg/8 mcg/40 D-antigen units/8 D-antigen units/32 D-antigen units)/0.5mL
- Lf = limits of flocculation
Immunization
For use as the 5th dose in the DTaP series and the 4th or 5th dose in the IPV series
<4 years: Safety and efficacy not established
4-6 years: 0.5 mL IM x 1 dose
Kinrix, Quadracel (diphtheria and tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine) adverse (side) effects
Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967
>10%
Injection site reactions including pain, redness, swelling (57%)
Drowsiness (19%)
Fever (16%)
Appetite loss (16%)
Redness (37%)
Swelling (26%)
Frequency not defined
Cerebrovascular accident
Cellulitis
Hypernatremia
Pruritus
Dehydration
Constipation
Angioedema
Seizures
Thrombocytopenia
Urticaria
Apnea
Lymphodenopathy
Warnings
Contraindications
Documented hypersensitivity
History of Arthus reaction to prior tetanus vaccination (unless 10 yr have elapsed)
History of encephalopathy (within 7 days of administration not attributable to other causes), progressive neurologic disorder with pertussis-containing vaccine
Progressive Neurologic Disorder
Infantile spasms, uncontrolled epilepsy, progressive encephalopathy
Do not administer pertussis vaccine until neurologic status is stabilized
Cautions
Tetanus toxoid carries risk for brachial neuritis, Guillain-Barre syndrome and anaphylaxis
Caution in Guillain-Barre syndrome within 6 wk of prior tetanus toxoid vaccine
Use caution in patients with history of seizure disorders, progressive neurologic disease, or conditions predisposing to seizures
Consider postponing administration iin patients with moderate or severe acute illness (with or without fever)
Use caution in severely immunocompromised patients
Pregnancy and lactation
Pregnancy category: C
Lactation: Excretion in milk unknown; use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Kinrix, Quadracel (diphtheria and tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine)
Mechanism of action
Production of specific antibodies to tetanus, diphtheria, and pertusis (active immunity)
Conveys active immunity via stimulation of production of endogenously produced antibodies